ASX - By Stock
|
IMU |
Re:
Ann: Azer-cel Hits Major Milestone in Phase 1b CAR T Trial
|
|
sagitarius
|
242 |
109K |
46 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
242
|
109K
|
46
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 CF33 VAXINIA Study Update - Positive Early Signals
|
|
sagitarius
|
315 |
144K |
47 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
315
|
144K
|
47
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Phase 1 onCARlytics CD19 virus clinical trial opens
|
|
sagitarius
|
174 |
79K |
29 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
174
|
79K
|
29
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Azer-cel FDA IND Transferred to Imugene
|
|
sagitarius
|
60 |
23K |
9 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
60
|
23K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Azer-cel FDA IND Transferred to Imugene
|
|
sagitarius
|
60 |
23K |
38 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
60
|
23K
|
38
|
|
ASX - By Stock
|
IMU |
Re:
Ann: VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1
|
|
sagitarius
|
58 |
26K |
31 |
04/09/23 |
04/09/23 |
ASX - By Stock
|
58
|
26K
|
31
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Trading Halt
|
|
sagitarius
|
264 |
98K |
1 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
264
|
98K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Trading Halt
|
|
sagitarius
|
264 |
98K |
8 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
264
|
98K
|
8
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy
|
|
sagitarius
|
107 |
56K |
54 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
107
|
56K
|
54
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene CF33 Oncolytic Virus Study to be Showcased at SITC
|
|
sagitarius
|
104 |
57K |
82 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
104
|
57K
|
82
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration
|
|
sagitarius
|
161 |
67K |
31 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
161
|
67K
|
31
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US
|
|
sagitarius
|
103 |
48K |
37 |
19/07/23 |
19/07/23 |
ASX - By Stock
|
103
|
48K
|
37
|
|
ASX - By Stock
|
IMU |
Re:
Ann: New Dose Escalation in Phase I Clinical Trial of CHECKvacc
|
|
sagitarius
|
96 |
43K |
35 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
96
|
43K
|
35
|
|
ASX - By Stock
|
IMU |
Re:
Ann: New Dose Escalation in Phase I Clinical Trial of CHECKvacc
|
|
sagitarius
|
96 |
43K |
39 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
96
|
43K
|
39
|
|
ASX - By Stock
|
IMU |
Re:
Ann: HER-Vaxx induced antibodies correlated with tumour reduction
|
|
sagitarius
|
156 |
72K |
21 |
30/06/23 |
30/06/23 |
ASX - By Stock
|
156
|
72K
|
21
|
|
ASX - By Stock
|
IMU |
Re:
Ann: HER-Vaxx induced antibodies correlated with tumour reduction
|
|
sagitarius
|
156 |
72K |
68 |
30/06/23 |
30/06/23 |
ASX - By Stock
|
156
|
72K
|
68
|
|
ASX - By Stock
|
IMU |
Re:
Ann: HER-Vaxx induced antibodies correlated with tumour reduction
|
|
sagitarius
|
156 |
72K |
70 |
30/06/23 |
30/06/23 |
ASX - By Stock
|
156
|
72K
|
70
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene PD1-Vaxx patent extended to 2040
|
|
sagitarius
|
112 |
43K |
9 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
112
|
43K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Target 2 cents
|
|
sagitarius
|
174 |
58K |
4 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
174
|
58K
|
4
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
sagitarius
|
22K |
11M |
14 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
22K
|
11M
|
14
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
|
|
sagitarius
|
233 |
107K |
85 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
233
|
107K
|
85
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene doses first combination patient in PD1-Vaxx trial
|
|
sagitarius
|
115 |
58K |
45 |
01/06/23 |
01/06/23 |
ASX - By Stock
|
115
|
58K
|
45
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
sagitarius
|
13K |
6.2M |
28 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
13K
|
6.2M
|
28
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
sagitarius
|
13K |
6.2M |
40 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
13K
|
6.2M
|
40
|
|
ASX - By Stock
|
IMU |
Re:
Ann: FDA clears Imugene IND for onCARlytics first-in-class study
|
|
sagitarius
|
148 |
65K |
73 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
148
|
65K
|
73
|
|
ASX - By Stock
|
IMU |
Re:
Ann: FDA clears Imugene IND for onCARlytics first-in-class study
|
|
sagitarius
|
148 |
65K |
62 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
148
|
65K
|
62
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
sagitarius
|
13K |
6.2M |
36 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
13K
|
6.2M
|
36
|
|
ASX - By Stock
|
IMU |
Re:
Ann: onCARlytics with ARTEMIS T cells show anti-tumour activity
|
|
sagitarius
|
129 |
52K |
13 |
18/05/23 |
18/05/23 |
ASX - By Stock
|
129
|
52K
|
13
|
|
ASX - By Stock
|
IMU |
Re:
Ann: onCARlytics with Artemis T cells abstract presented at ASGCT
|
|
sagitarius
|
95 |
43K |
22 |
03/05/23 |
03/05/23 |
ASX - By Stock
|
95
|
43K
|
22
|
|
ASX - By Stock
|
IMU |
Re:
Ann: onCARlytics with Artemis T cells abstract presented at ASGCT
|
|
sagitarius
|
95 |
43K |
52 |
03/05/23 |
03/05/23 |
ASX - By Stock
|
95
|
43K
|
52
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene receives $12.6m R&D tax refund
|
|
sagitarius
|
107 |
42K |
21 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
107
|
42K
|
21
|
|
ASX - By Stock
|
IMU Biotech |
Re:
The CF33, Vaxinia and Oncarlytics Deal
|
|
sagitarius
|
1.0K |
633K |
9 |
23/04/23 |
23/04/23 |
ASX - By Stock
|
1.0K
|
633K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
IMU-Trading Thread
|
|
sagitarius
|
140 |
56K |
32 |
22/04/23 |
22/04/23 |
ASX - By Stock
|
140
|
56K
|
32
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Images and Follows CHECKVacc in TNBC Patients
|
|
sagitarius
|
117 |
62K |
42 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
117
|
62K
|
42
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Images and Follows CHECKVacc in TNBC Patients
|
|
sagitarius
|
117 |
62K |
53 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
117
|
62K
|
53
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
sagitarius
|
13K |
6.2M |
37 |
10/04/23 |
10/04/23 |
ASX - By Stock
|
13K
|
6.2M
|
37
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
sagitarius
|
13K |
6.2M |
43 |
09/04/23 |
09/04/23 |
ASX - By Stock
|
13K
|
6.2M
|
43
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
sagitarius
|
13K |
6.2M |
34 |
09/04/23 |
09/04/23 |
ASX - By Stock
|
13K
|
6.2M
|
34
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
sagitarius
|
22K |
11M |
29 |
08/04/23 |
08/04/23 |
ASX - By Stock
|
22K
|
11M
|
29
|
|
ASX - By Stock
|
IMU |
Re:
Ann: First patients dosed in IT & IV cohort 3 of VAXINIA trial
|
|
sagitarius
|
89 |
51K |
25 |
05/04/23 |
05/04/23 |
ASX - By Stock
|
89
|
51K
|
25
|
|
ASX - By Stock
|
IMU |
Re:
Ann: First Patients Dosed in Combination Study of VAXINIA
|
|
sagitarius
|
43 |
25K |
43 |
03/03/23 |
03/03/23 |
ASX - By Stock
|
43
|
25K
|
43
|
|
ASX - By Stock
|
IMU |
Re:
So Exactly Who Is Feeling Like a Goose Now
|
|
sagitarius
|
114 |
49K |
11 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
114
|
49K
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
sagitarius
|
13K |
6.2M |
62 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
13K
|
6.2M
|
62
|
|
ASX - By Stock
|
IMU |
Re:
Where’s the bottom?
|
|
sagitarius
|
74 |
31K |
19 |
13/02/23 |
13/02/23 |
ASX - By Stock
|
74
|
31K
|
19
|
|
ASX - By Stock
|
IMU |
Re:
Where’s the bottom?
|
|
sagitarius
|
74 |
31K |
7 |
13/02/23 |
13/02/23 |
ASX - By Stock
|
74
|
31K
|
7
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
sagitarius
|
13K |
6.2M |
33 |
11/02/23 |
11/02/23 |
ASX - By Stock
|
13K
|
6.2M
|
33
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
sagitarius
|
13K |
6.2M |
25 |
11/02/23 |
11/02/23 |
ASX - By Stock
|
13K
|
6.2M
|
25
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
|
|
sagitarius
|
109 |
53K |
14 |
10/02/23 |
10/02/23 |
ASX - By Stock
|
109
|
53K
|
14
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
|
|
sagitarius
|
109 |
53K |
22 |
10/02/23 |
10/02/23 |
ASX - By Stock
|
109
|
53K
|
22
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
|
|
sagitarius
|
109 |
53K |
51 |
10/02/23 |
10/02/23 |
ASX - By Stock
|
109
|
53K
|
51
|
|